Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    23883377 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Condition: Pulmonary Hypertension
Intervention: Drug: Riociguat (Adempas, BAY63-2521)
2 Completed
Has Results
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
3 Recruiting Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
Conditions: Hypertension, Pulmonary;   Altitude Sickness
Intervention: Drug: Riociguat

Indicates status has not been verified in more than two years